A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

<p>Abstract</p> <p>Background</p> <p>Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients w...

Full description

Bibliographic Details
Main Authors: Wun Ted, Soulieres Denis, Frelinger Andrew L, Krishnamurti Lakshmanan, Novelli Enrico M, Kutlar Abdullah, Ataga Kenneth I, Knupp Charles L, McMahon Lillian E, Strouse John J, Zhou Chunmei, Heath Lori E, Nwachuku Chuke E, Jakubowski Joseph A, Riesmeyer Jeffrey S, Winters Kenneth J
Format: Article
Language:English
Published: BMC 2013-02-01
Series:Journal of Hematology & Oncology
Subjects:
Prasugrel
Sickle cell disease
Thienopyridine
Platelet function
Online Access:http://www.jhoonline.org/content/6/1/17

Internet

http://www.jhoonline.org/content/6/1/17

Similar Items